Social and Clinical Determinants of Contralateral Prophylactic Mastectomy

Authors:

Abstract
A patient’s decision to undergo contralateral prophylactic mastectomy (CPM) as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removal of the unaffected breast in most patients diagnosed as having breast cancer has not been shown to prolong survival.1 Additionally, the widespread use of adjuvant therapy even for small node–negative breast cancers has resulted in a decrease in the incidence of contralateral breast cancer of approximately 3% per year since 1985.2 Subgroups of patients with breast cancer at increased risk for development of contralateral cancer, and in whom having the nonaffected breast removed could improve survival, have been identified. Indeed, the Society of Surgical Oncology suggests that CPM should be considered in the minority of patients at higher than average risk for developing contralateral breast cancer, specifically those patients with either: (1) a genetic mutation of BRCA1 or BRCA2 or another known mutation or (2) a strong family history of at least 2 first-degree relatives with breast or ovarian cancer with no demonstrable mutations.3 It is estimated that fewer than 10% of women with newly diagnosed unilateral breast cancer have 1 or both of these clinical indications.4-6 Despite the cautious approach to CPM outlined in these recommendations, rates have been steadily increasing during the past decade.4,7-10

This publication has 37 references indexed in Scilit: